Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, 80523, USA.
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, 80523, USA.
Vet Comp Oncol. 2016 Dec;14(4):371-383. doi: 10.1111/vco.12117. Epub 2014 Sep 11.
Feline oral squamous cell carcinoma (SCC) has very poor prognosis. Here, a retrospective pilot study was conducted on 20 feline oral SCC patients who underwent stereotactic radiation therapy (SRT), to evaluate: (1) the value of putative tumour initiating cell (TIC) markers of human head and neck SCC (CD44, Bmi-1); (2) telomere length (TL) specifically in putative TICs; and (3) tumour relative telomerase activity (TA). Significant inverse correlations were found between treatment outcomes and Bmi-1 expression, supporting the predictive value of Bmi-1 as a negative prognostic indicator. While TL exhibited a wide range of variability, particularly in very short fractions, many tumours possessed high levels of TA, which correlated with high levels of Bmi-1, Ki67 and EGFR. Taken together, our results imply that Bmi-1 and telomerase may represent novel therapeutic targets in feline oral SCC, as their inhibition - in combination with SRT - would be expected to have beneficial treatment outcome.
猫口腔鳞状细胞癌（SCC）的预后非常差。在这里，对 20 例接受立体定向放射治疗（SRT）的猫口腔 SCC 患者进行了回顾性试点研究，以评估：（1）人类头颈部 SCC 的假定肿瘤起始细胞（TIC）标志物 CD44、Bmi-1 的价值；（2）特定于假定 TIC 的端粒长度（TL）；和（3）肿瘤相对端粒酶活性（TA）。治疗结果与 Bmi-1 表达呈显著负相关，支持 Bmi-1 作为负预后指标的预测价值。虽然 TL 表现出广泛的变异性，尤其是在非常短的片段中，但许多肿瘤具有高水平的 TA，这与高水平的 Bmi-1、Ki67 和 EGFR 相关。综上所述，我们的研究结果表明，Bmi-1 和端粒酶可能是猫口腔 SCC 的新的治疗靶点，因为它们的抑制 - 结合 SRT - 预计会有有益的治疗效果。
